CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers
- 172 Downloads
The polymorphic genetic differences among individuals may modify the high risk for breast cancer (BC) and/or ovarian cancer (OC) susceptibility conferred by BRCA1 and BRCA2 mutations. In the present study we investigate the relevance of RAD51 −135C > G, TP53 R72P, NQO1*2 and CASP8 D302H polymorphisms as potential modifiers of BC and/or OC susceptibility conferred by these mutations. The study group encompasses 390 BRCA1/BRCA2 mutation carriers (182 affected with BC and/or OC and 208 unaffected) of 131 unrelated families studied in the Program of Genetic Counselling on Cancer of Valencia Community. The polymorphisms were detected in genomic DNA by ASRA method or real time PCR using fluorescently labeled probes. We found similar incidence of RAD51 −135C > G, TP53 R72P and NQO1*2 polymorphisms among affected and unaffected individuals considering BRCA1/BRCA2 mutations together and separately. However, the CASP8 D302H polymorphism was strongly associated with the absence of BC [OR = 3.41 (95% CI 1.33–8.78, P = 0.01)]. In fact, in the females with CASP8 D302H polymorphism the BC appeared at a median age of 58 in opposition to the 47 years observed for the wild type subjects (P = 0.03). Furthermore, the CASP8 D302H positive females showed a 50% probability of being free of BC by the age of 78 versus the 2% of the CASP8 negative ones. Our results support that the presence of the CASP8 D302H polymorphism diminishes the high risk of BC conferred by BRCA1 and BRCA2 mutations, making possible that some of the carriers could escape from suffering BC along their life span.
KeywordsBRCA1/BRCA2 mutation carriers Breast cancer CASP8 D302H polymorphism
This study has been performed with the financial support of grant AP 019/06 from the “Conselleria de Sanitat de la Generalitat Valenciana”. Sarai Palanca and Inmaculada de Juan (Bch Sc and Specialists in Clinical Analysis) were recipients of fellowships from the “Fundación para Investigación del Hospital Universitario La Fe”. We also should express our gratitude to Dr. Dolores Cuevas Cuerda (Jefa de Servicio de Protocolización e Integración Asistencial, Dirección de Asistencia Sanitaria, Consellería de Sanitat, Generalitat Valenciana) and Dolores Salas Trejo (Jefa de Servicio de la Oficina del Plan de Cáncer, Dirección General de Salud Pública, Consellería de Sanitat, Generalitat Valenciana) for her help and strong support given for the establishment and development of the Program of Genetic Counselling in Cancer of Valencia Community.
- 7.Chenevix-Trench G, Milne RL, Antoniou AC et al (2007) An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the consortium of investigators of modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 9:104. doi: 10.1186/bcr1670 CrossRefPubMedGoogle Scholar
- 35.The Breast Cancer Information Core Database BIC. http://research.nhgri.nih.gov/bic/Member/index.shtml. Accessed 1 Jan 2009
- 36.Ganguly A, Rock MJ, Prockop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci USA 90:10325–10329. doi: 10.1073/pnas.90.21.10325 CrossRefPubMedGoogle Scholar
- 43.De Vecchi G, Verderio P, Pizzamiglio S, et al. (2008) Evidences for association of the CASP8 −652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Res Treat (in press)Google Scholar